Gt biopharma announces fda data - gtb-3550 trike™ reduces cancer cells by 61.7% for a high-risk myelodysplastic syndromes (hr-mds) patient

Beverly hills, calif, dec. 21, 2020 /prnewswire/ -- gt biopharma, inc. (otcqb: gtbp) (gtbp.pa) an immuno-oncology company focused on innovative therapies based on the company's proprietary nk cell engager (trike™) technology platform is pleased to announce the presentation of additional...

GTBP Ratings Summary

GTBP Quant Ranking